Skip to main content
NCBI home page
Journal of Cellular and Molecular Medicine logoLink to Journal of Cellular and Molecular Medicine
. 2007 May 1;9(1):208–221. doi: 10.1111/j.1582-4934.2005.tb00350.x

Understanding breast cancer risk ‐ where do we stand in 2005?

R G Dumitrescu 1,✉, I Cotarla 1
PMCID: PMC6741339  PMID: 15784178

Abstract

Breast cancer is the most frequent cancer in women and represents the second leading cause of cancer death among women (after lung cancer). The etiology of breast cancer is still poorly understood with known breast cancer risk factors explaining only a small proportion of cases. Risk factors that modulate the development of breast cancer discussed in this review include: age, geographic location (country of origin) and socioeconomic status, reproductive events, exogenous hormones, lifestyle risk factors (alcohol, diet, obesity and physical activity), familial history of breast cancer, mammographic density, history of benign breast disease, ionizing radiation, bone density, height, IGF‐1 and prolactin levels, chemopreventive agents. Additionally, we summarized breast cancer risk associated with the following genetic factors: breast cancer susceptibility high‐penetrance genes (BRCA1, BRCA2, p53, PTEN, ATM, NBS1 or LKB1) and low‐penetrance genes such as cytochrome P450 genes (CYP1A1, CYP2D6, CYP19), glutathione S‐transferase family (GSTM1, GSTP1), alcohol and one‐carbon metabolism genes (ADH1C and MTHFR), DNA repair genes (XRCC1, XRCC3, ERCC4/XPF) and genes encoding cell signaling molecules (PR, ER, TNFα or HSP70). All these factors contribute to a better understanding of breast cancer risk. Nonetheless, in order to evaluate more accurately the overall risk of breast tumorigenesis, novel genetic and phenotypic traits need to be identified.

Keywords: breast cancer, risk factors, high‐penetrance genes, low‐penetrance genes

References

  • 1. Parkin D. M., International variation, Oncogene, 23: 6329–6340, 2004. [DOI] [PubMed] [Google Scholar]
  • 2. Stewart S. L., King J. B., Thompson T. D., Friedman C., Wingo P. A., Cancer mortality surveillance–United States, 1990–2000, MMWR. Surveill. Summ., 53: 1–108, 2004. [PubMed] [Google Scholar]
  • 3. Jemal A., Thomas A., Murray T., Thun M., Cancer statistics, 2002, CA Cancer. J.Clin., 52: 23–47, 2002. [DOI] [PubMed] [Google Scholar]
  • 4. Bray F., Sankila R., Ferlay J., Parkin D. M., Estimates of cancer incidence and mortality in Europe in 1995, Eur. J. Cancer, 38: 99–166, 2002. [DOI] [PubMed] [Google Scholar]
  • 5. Edwards B. K., Howe H. L., Ries L. A., Thun M. J., Rosenberg H. M., Yancik R., Wingo P. A., Jemal A., Feigal E. G., Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and againg on U.S. Cancer burden, Cancer, 94: 2766–2792, 2002. [DOI] [PubMed] [Google Scholar]
  • 6. Hulka B. S., Moorman P. G., Breast cancer: hormones and other risk factor, Maturitas, 38: 103–113, 2001. [DOI] [PubMed] [Google Scholar]
  • 7. Pike M. C., Spicer D. V., Dahmoush L., Press M. F., Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk, Epidemiol. Rev., 15: 17–35, 1993. [DOI] [PubMed] [Google Scholar]
  • 8. Parkin D. M., Pisani P., Ferlay J., Global cancer statistics, CA Cancer J. Clin., 49: 33–64, 1, 1999. [DOI] [PubMed] [Google Scholar]
  • 9. Ziegler R. G., Hoover R. N., Pike M. C., Hildesheim A., Nomura A. M., West D. W., Wu‐Williams A. H., Kolonel L. N., Horn‐Ross P. L., Rosenthal J. F., Migration Patterns and breast cancer risk in Asian‐American women, J. Natl. Cancer Inst., 85: 1819–1827, 1993. [DOI] [PubMed] [Google Scholar]
  • 10. McPherson K., Steel C. M., Dixon J. M., ABC of breast diseases. Breast cancer‐epidemiology, risk factors, and genetics, BMJ, 321: 624–628, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Robert S. A., Strombom I., Trentham‐Dietz A., Hampton J. M., McElroy J. A., Newcomb P. A., Remington P. L., Socioeconomic risk factors for breast cancer: distinguishing individual‐ and community‐level effects, Epidemiology, 15: 442–450, 2004. [DOI] [PubMed] [Google Scholar]
  • 12. Feigelson H. S., Henderson B. E., Estrogens and breast cancer, Carcinogenesis, 17: 2279–2284, 1996. [DOI] [PubMed] [Google Scholar]
  • 13. Berkey C. S., Frazier A. L., Gardner J. D., Colditz G. A., Adolescence and breast carcinoma risk, Cancer, 85: 2400–2409, 1999. [DOI] [PubMed] [Google Scholar]
  • 14. Kelsey J. L., Gammon M. D., John E. M., Reproductive factors and breast cancer, Epidemiol.Rev., 15: 36–47, 1993. [DOI] [PubMed] [Google Scholar]
  • 15. Titus‐Ernstoff L., Longnecker M. P., Newcomb P. A., Dain B., Greenberg E. R., Mittendorf R., Stampfer M., Willett W., Menstrual factors in relation to breast cancer risk, Cancer Epidemiol.Biomarkers Prev., 7: 783–789, 1998. [PubMed] [Google Scholar]
  • 16. Brinton L. A., Schairer C., Hoover R. N., Fraumeni J. F., Jr. , Menstrual factors and risk of breast cancer, Cancer Invest, 6: 245–254, 1988. [DOI] [PubMed] [Google Scholar]
  • 17. Bernstein L., Epidemiology of endocrine‐related risk factors for breast cancer, J. Mammary. Gland. Biol. Neoplasio., 7: 3–15, 2002. [DOI] [PubMed] [Google Scholar]
  • 18. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with brest cancer and 100 239 women without breast cancer form 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet, 347: 1713–1727, 1996. [DOI] [PubMed] [Google Scholar]
  • 19. Kreiger N., Sloan M., Cotterchio M., Kirsh V., The risk of breast cancer following reproductive surgery, European Journal of Cancer, 35: 97–101, 1999. [DOI] [PubMed] [Google Scholar]
  • 20. Russo J., Hu Y. F., Yang X., Russo I. H., Developmental, cellular, and molecular basis of human breast cancer, J. Natl. Cancer. Inst. Monogr. , 17–37, 2000. [DOI] [PubMed]
  • 21. Pathak D. R., Osuch J. R., He J., Breast carcinoma etiology: current knowledge and new insights into the effects of reproductive and hormonal risk factors in black and white populations, Cancer, 88: 1230–1238, 2000. [DOI] [PubMed] [Google Scholar]
  • 22. Lambe M., Hsieh C., Trichopoulos D., Ekbom A., Pavia M., Adami H. O., Transient increase in the risk of breast cancer after giving birth, N. Engl. J. Med., 331: 5–9, 1994. [DOI] [PubMed] [Google Scholar]
  • 23. Helewa M., Levesque P., Provencher D., Lea R. H., Rosolwich V., Shapiro H. M., Breast cancer, pregnancy, and breastfeeding, J. Obstet. Gynaecol. Can., 24: 164–180, 2002. [PubMed] [Google Scholar]
  • 24. Lipworth L., Bailey L. R., Trichopoulos D., History of breast‐feeding in relation to breast cancer risk: a review of the epidemiologic literature, J. Natl. Cancer. Inst., 92: 302–312, 2000. [DOI] [PubMed] [Google Scholar]
  • 25. Beral V., Breast cancer and breastfeeding: collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease, The Lancet, 360; 187–195, 2002. [DOI] [PubMed] [Google Scholar]
  • 26. Sivaraman L., Medina D., Hormone‐induced protection against breast cancer, J. Mammary. Glangd. Biol. Neoplasia., 7: 77–92, 2002. [DOI] [PubMed] [Google Scholar]
  • 27. Ross R. K., Paganini‐Hill A., Wan P. C., Pike M. C., Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin, J. Natl. Cancer Inst., 92: 328–332, 2000. [DOI] [PubMed] [Google Scholar]
  • 28. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan‐Chiu E., Ford L., Wolmark N., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel and Project P‐1 Study, J. Natl. Cancer Inst., 90: 1371–1388, 1998. [DOI] [PubMed] [Google Scholar]
  • 29. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer, Lancet, 350: 1047–1059, 1997. [PubMed] [Google Scholar]
  • 30. Rossouw J. E., Anderson G. L., Prentice R. L., LaCroix A. Z., Kooperberg C., Stefanick M. L., Jackson R. D., Beresford S. A., Howard B. V., Johnson K. C., Kotchen J. M., Ockene J., Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal resutls From the Women's Health Initiative randomized controlled trial, JAMA, 288: 321–333, 2002. [DOI] [PubMed] [Google Scholar]
  • 31. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinotn L., Hoover R., Menopausal estrogen and estrogen‐progestin replacement therapy and breast cancer risk, JAMA, 283: 485–491, 2000. [DOI] [PubMed] [Google Scholar]
  • 32. Magnusson C., Baron J. A., Correia N., Bergstrom R., Adami H. O., Persson I., Breast‐cancer risk followilng long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy, Int. J. Cancer., 81: 339–334, 1999. [DOI] [PubMed] [Google Scholar]
  • 33. Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer, Contraception, 54: 1S–106S, 1996. [DOI] [PubMed] [Google Scholar]
  • 34. Grabrick D. M., Hartmann L. C., Cerhan J. R., Vierkant R. A., Therneau T. M., Vachon C. M., Olson J. E., Couch F. J., Anderson K. E., Pankratz V. S., Sellers T. A., Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer, JAMA, 284: 1791–1798, 2000. [DOI] [PubMed] [Google Scholar]
  • 35. Heimdal K., Skovlund E., Moller P., Oral contraceptives and risk of familial breast cancer, Cancer. Detect. Prev., 26: 23–27, 2002. [DOI] [PubMed] [Google Scholar]
  • 36. Singletary K. W., Gapstur S. M., Alcohol and breast cancer: review of epidemiologic and experimental evidence and potential mechanisms, JAMA, 286: 2143–2151, 2001. [DOI] [PubMed] [Google Scholar]
  • 37. Smith‐Warner S. A., Spiegelamn D., Yaun S. S., van den Brandt P. A., Folsom A. R., Goldbohm R. A., Graham S., Holmberg L., Howe G. R., Marshall J. R., Miller A. B., Poter J. D., Speizer F. E., Willett W. C., Wolk A., Hunter D. J., Alcohol and breast cancer in women: a pooled analysis of cohort studies, JAMA, 279: 535–540, 1998. [DOI] [PubMed] [Google Scholar]
  • 38. Poschl G., Seitz H. K., Alcohol and cancer, Alcohol Alcohol, 39: 155–165, 2004. [DOI] [PubMed] [Google Scholar]
  • 39. Reichman M. E., Judd J. T., Longcope C., Schatzkin A., Clevidence B. A., Nair P. P., Campbell W. S., Taylor P. R., Effects of alcohol consumption on plasma and urinary hormone concentrations in premenopausal women, J. Natl. Cancer Inst., 85: 722–727, 1993. [DOI] [PubMed] [Google Scholar]
  • 40. Coutelle C., Hohn B., Benesova M., Oneta C. M., Quattrochi P., Roth H. J., Schmidt‐Gayk H., Schneeweiss A., Bastert G., Seitz H. K., Risk factors in alcohol associated breast cancer: alcohol dehydrogenase polymorphism and estrogens, Int. J. Oncol., 25: 1127–1132, 2004. [PubMed] [Google Scholar]
  • 41. Ginsburg E. S., Walsh B. W., Gao X., Gleason R. E., Feltmate C., Barbieri R. L., The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol, J. Soc. Gynecol. Investig., 2: 26–29, 1995. [PubMed] [Google Scholar]
  • 42. Onland‐Moret N. C., Peeters P. H., van der Schouw Y. T., Grobbee D. E., Van Gils C. H., Alcohol and Endogenous Sex Steroid Levels in Postmenopausal Women: a cross‐sectional study, J. Clin. Endocrinol. Metab. , 2004. [DOI] [PubMed]
  • 43. Sellers T. A., Vierkant R. A., Cerhan J. R., Gapstur S. M., Vachon C. M., Olson J. E., Pankratz V. S., Kushi L. H., Folsom A. R., Interaction of dietary folate intake, alcohol, and risk of hormone receptor‐defined breast cancer in a prospective study of postmenopausal women, Cancer Epidemiol. Biomarkers Prev., 11: 1104–1107, 2002. [PubMed] [Google Scholar]
  • 44. Duthie S. J., Folic acid deficiency and cancer: mechanisms of DNA instability, Br. Med. Bull., 55: 578–592, 1999. [DOI] [PubMed] [Google Scholar]
  • 45. Zhang S. M., Role of vitamins in the risk, prevention, and treatment of breast cancer, Curr. Opin. Obstet. Gynecol., 16: 19–25, 2004. [DOI] [PubMed] [Google Scholar]
  • 46. Sugimura T., Nutrition and dietary carcinogens, Carcinogenesis, 21: 387–395, 2000. [DOI] [PubMed] [Google Scholar]
  • 47. Zheng W., Gustafson D. R., Sinha R., Cerhan J. R., Moore D., Hong C. P., Anderson K. E., Kushi L. H., Sellers T. A., Folsom A. R., Well‐done meat intake and the risk of breast cancer, J. Natl. Cancer Inst., 90: 1724–1729, 1998. [DOI] [PubMed] [Google Scholar]
  • 48. Velie E., Kulldorff M., Schairer C., Block G., Albanes D., Schatzkin A., Dietary fat, fat subtypes, and breast cancer in postmenopausal women: a prospective cohort study, J. Natl. Cancer Inst., 92: 833–839, 2000. [DOI] [PubMed] [Google Scholar]
  • 49. Bartsch H., Nair J., Owen R. W., Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers, Carcinogenesis, 20: 2209–2218, 1999. [DOI] [PubMed] [Google Scholar]
  • 50. Saadatian‐Elahi M., Norat T., Goudable J., Riboli E., Biomarkers of dietary fatty acid intake and the risk of breast cancer: a meta‐analysis, Int. J. Cancer, 111: 584–591, 2004. [DOI] [PubMed] [Google Scholar]
  • 51. Van Duyn M. A., Pivonka E., Overview of the Health Benefits of Fruit and Vegetable Consumption for the Dietetics Professional: Selected Literature, J. Am. Diet Assoc., 100: 1511–1521, 2000. [DOI] [PubMed] [Google Scholar]
  • 52. Lee I. M., Antioxidant vitamins in the prevention of cancer, Proc. Assoc. Am. Physicians, 111: 10–15, 1999. [DOI] [PubMed] [Google Scholar]
  • 53. Gaudet M. M., Britton J. A., Kabat G. C., Steck‐Scott S., Eng S. M., Teitelbaum S. L., Terry M. B., Neugut A. I., Gammon M. D., Fruits, Vegetables, and Micronutrients in Relation to Breast Cancer Modified by Menopause and Hormone Receptor Status, Cancer Epidemiol. Biomarkers Prev., 13: 1485–1494, 2004. [PubMed] [Google Scholar]
  • 54. Bouker K. B., Hilakivi‐Clarke L., Genistein: does it prevent or promote breast cancer?, Environ. Health Perspect., 108: 701–708, 2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Harris R. E., Namboodiri K. K., Wynder E. L., Breast cancer risk: effects of estrogen replacement therapy and body mass, J. Natl. Cancer Inst., 84: 1575–1582, 1992. [DOI] [PubMed] [Google Scholar]
  • 56. Huang Z., Hankinson S. E., Colditz G. A., Stampfer M. J., Hunter D. J., Manson J. E., Hennekens C. H., Rosner B., Speizer F. E., Willett W. C., Dual effects of weight and weight gain on breast cancer risk, JAMA, 278: 1407–1411, 1997. [PubMed] [Google Scholar]
  • 57. Lahmann P. H., Hoffmann K., Allen N., Van Gils C. H., Khaw K. T., Tehard B., Berrino F., Tjonneland A., Bigaard J., Olsen A., Overvad K., Clavel‐Chapelon F., Nagel G., Boeing H., Trichopoulos D., Economou G., Bellos G., Palli D., Tumino R., Panico S., Sacerdote C., Krogh V., Peeters P. H., Bueno‐de‐Mesquita H. B., Lund E., Ardanaz E., Amiano P., Pera G., Quiros J. R., Martinez C., Tormo M. J., Wirfalt E., Berglund G., Hallmans G., Key T. J., Reeves G., Bingham S., Norat T., Biessy C., Kaaks R., Riboli E., Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC), Int. J. Cancer, 111: 762–771, 2004. [DOI] [PubMed] [Google Scholar]
  • 58. Friedenreich C. M., Review of anthropometric factors and breast cancer risk, Eur. J. Cancer Prev., 10: 15–32, 2001. [DOI] [PubMed] [Google Scholar]
  • 59. Trentham‐Dietz A., Newcomb P. A., Egan K. M., Titus‐Ernstoff L., Baron J. A., Storer B. E., Stampfer M., Willett W. C., Weight change and risk of postmenopausal breast cancer (United States), Cancer Causes Control, 11: 533–542, 2000. [DOI] [PubMed] [Google Scholar]
  • 60. McTiernan A., Rajan K. B., Tworoger S. S., Irwin M., Bernstein L., Baumgartner R., Gilliland F., Stanczyk F. Z., Yasui Y., Ballard‐Barbash R., Adiposity and Sex Hormones in Postmeopausal Breast Cancer Survivors, J. Clin. Oncol., 21: 1961–1966, 2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Lagerros Y. T., Hsieh S. F., Hsieh C. C., Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review, Eur. J. Cancer Prev., 13: 5–12, 2004. [DOI] [PubMed] [Google Scholar]
  • 62. Hankinson S. E., Colditz G. A., Willett W. C., Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones, Breast Cancer Res., 6: 213–218, 2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease, Lancet, 358: 1389–1399, 2001. [DOI] [PubMed] [Google Scholar]
  • 64. Brinton L. A., Hoover R., Haile R., Mammographic features and breast cancer risk: effects with time, age, and menopause status, J. Natl. Cancer Inst., 87: 1622–1629, 1995. [DOI] [PubMed] [Google Scholar]
  • 65. Boyd N. F., Byng J. W., Jong R. A., Fishell E. K., Little L. E., Miller A. B., Lockwood G. A., Tritchler D. L., Yaffe M. J., Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study, J. Natl. Cancer Inst., 87: 670–675, 1995. [DOI] [PubMed] [Google Scholar]
  • 66. Biglia N., Defabiani E., Ponzone R., Mariani L., Marenco D., Sismondi P., Management of risk of breast carcinoma in postmenopausal women, Endocr: Relat. Cancer, 11: 69–83, 2004. [DOI] [PubMed] [Google Scholar]
  • 67. Van Gils C. H., Hendriks J. H., Otten J. D., Holland R., Verbeek A. L., Parity and mammographic breast density in relation to breast cancer risk: indication of interaction, Eur: J. Cancer Prev., 9: 105–111, 2000. [DOI] [PubMed] [Google Scholar]
  • 68. Sala E., Warren R., McCann J., Duffy S., Luben R., Day N., High‐risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case‐control study, Int. J. Epidemiol., 29: 629–636, 2000. [DOI] [PubMed] [Google Scholar]
  • 69. Cauley J. A., Gutai J. P., Kuller L. H., Scott J., Nevitt M. C., Black‐white differences in serum sex hormones and bone mineral density, Am. J. Epidemiol., 139: 1035–1046, 1994. [DOI] [PubMed] [Google Scholar]
  • 70. van den Brandt P.A., Spiegelman D., Yaun S. S., Adami H. O., Beeson L., Folsom A. R., Fraser G., Goldbohm R. A., Graham S., Kushi L., Marshall J. R., Miller A. B., Rohan T., Smith‐Warner S. A., Speizer F. E., Willett W. C., Wolk A., Hunter D. J., Pooled Analysis of Prospective Cohort Studies on Height, Weight, and Breast Cancer Risk, American Journal of Epidemiology, 152: 514–527, 2000. [DOI] [PubMed] [Google Scholar]
  • 71. Renehan A. G., Zwahlen M., Minder C., O'Dwyer S. T., Shalet S. M., Egger M., Insulin‐like growth factor (IGF)‐I, IGF binding protein‐3, and cancer risk: systematic review and meta‐regression analysis, Lancet, 363: 1346–1353, 2004. [DOI] [PubMed] [Google Scholar]
  • 72. Yu H., Shu X. O., Li B. D. L., Dai Q., Gao Y. T., Jin F., Zheng W., Joint Effect of Insulin‐like Growth Factors and Sex Steriods on Breast Cancer Risk, Cancer Epidemiol. Biomarkers Prev., 12: 1067–1073, 2003. [PubMed] [Google Scholar]
  • 73. Clevenger C. V., Furth P. A., Hankinson S. E., Schuler L. A., The role of prolactin in mammary carcinoma, Endocr. Rev, 24: 1–27, 2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Hankinson S. E., Willett W. C., Michaud D. S., Manson J. E., Colditz G. A., Longcope C., Rosner B., Speizer F. E., Plasma prolactin levels and subsequent risk of breast cancer in postmenopusal women, J. Natl. Cancer Inst., 91: 629–634, 1999. [DOI] [PubMed] [Google Scholar]
  • 75. Cotarla I., Ren S., Zhang Y., Gehan E., Singh B., Furth P.A., Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers, Int. J. Cancer, 108: 665–671, 2004. [DOI] [PubMed] [Google Scholar]
  • 76. Tobias J. S., J. S., Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention, Ann. Oncol., 15: 1738–1747, 2004. [DOI] [PubMed] [Google Scholar]
  • 77. Arun B., Goss P., The role of COX‐2 inhibition in breast cancer treatment and prevention, Semin. Oncol., 31: 22–29, 2004. [DOI] [PubMed] [Google Scholar]
  • 78. Easton D., Ford D., Peto J., Inherited susceptibility to breast cancer, Cancer Surv., 18: 95–113, 1993. [PubMed] [Google Scholar]
  • 79. Oesterreich S., Fuqua S. A., Tumor suppressor genes in breast cancer, Endocr. Relat. Cancer, 6: 405–419, 1999. [DOI] [PubMed] [Google Scholar]
  • 80. Johnson‐ Thompson M. C., Guthrie J., Ongoing research to identify environmental risk factors in breast carcinoma, Cancer, 88: 1224–1229, 2000. [DOI] [PubMed] [Google Scholar]
  • 81. Rebbeck T. R., Inherited genetic predisposition in breast cancer. A population‐based perspective, Cancer, 86: 2493–2501, 1999. [DOI] [PubMed] [Google Scholar]
  • 82. De Jong M. M., Nolte I. M., Te Meerman G. J., van der Graaf W. T., Oosterwijk J. C., Kleibeuker J. H., Schaapveld M., De Vries E. G., Genes Other than BRCA1 and BRCA2 involved in breast cancer susceptibility, J. Med. Genet., 39: 225–242, 2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Deng C. X., Brodie S. G., Roles of BRCA1 and its interacting proteins, Bioessays, 22: 728–737, 2000. [DOI] [PubMed] [Google Scholar]
  • 84. Narod S. A., Modifiers of risk of hereditary breast and ovarian cancer, Nat. Rev. Cancer, 2: 113–123, 2002. [DOI] [PubMed] [Google Scholar]
  • 85. King M. C., Marks J. H., Mandell J. B., Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2, Science, 302: 643–646, 2003. [DOI] [PubMed] [Google Scholar]
  • 86. Ford D., Easton D. F., Stratton M., Narod S., Goldgar D., Devilee P., Bishop D. T., Weber B., Lenoir G., Chang‐Claude J., Sobol H., Teare M. D., Struewing J., Arason A., Scherneck S., Peto J., Rebbeck T. R., Tonin P., Neuhausen S., Barkardottir R., Eyfjord J., Lynch H., Ponder B. A., Gayther S. A., Zelada‐Hedman M., Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium, Am. J. Hum. Genet., 62: 676–689, 1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Osorio A., de la H. M. , Rodriguez‐Lopez R., Martinez‐Ramirez A., Cazorla A., Granizo J.J., Esteller M., Rivas C., Caldes T., Benitez J., Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer, Int. J. Cancer, 99: 305–309, 2002. [DOI] [PubMed] [Google Scholar]
  • 88. Eiriksdottir G., Barkardottir R. B., Agnarsson B. A., Johannesdottir G., Olafsdottir K., Egilsson V., Ingvarsson S., High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers, Oncogene, 16: 21–26, 1998. [DOI] [PubMed] [Google Scholar]
  • 89. Venkitaraman A. R., Tracing the network connecting BRCA and Fanconi anaemia proteins, Nat. Rev. Cancer, 4: 266–276, 2004. [DOI] [PubMed] [Google Scholar]
  • 90. Malkin D., Germline p53 mutations and heritable cancer, Annu. Rev. Genet., 28: 443–465, 1994. [DOI] [PubMed] [Google Scholar]
  • 91. Garber J. E., Goldstein A. M., Kantor A. F., Dreyfus M. G., Fraumeni J. F., Jr. , Li F.P., Follow‐up study of twentyfour families with Li‐Fraumeni syndrome, Cancer Res., 51: 6094–6097, 1991. [PubMed] [Google Scholar]
  • 92. Easton D. F., The inherited component of cancer, Br. Med. Bull., 50: 527–535, 1994. [DOI] [PubMed] [Google Scholar]
  • 93. Gorski B., Debniak T., Masojc B., Mierzejewski M., Medrek K., Cybulski C., Jakubowska A., Kurzawski G., Chosia M., Scott R., Lubinski J., Germline 657de15 mutation in the NBS1 gene in breast cancer patients, Int. J. Cancer, 106: 379–381, 2003. [DOI] [PubMed] [Google Scholar]
  • 94. Rothman N., Wacholder S., Caporaso N. E., Garcia‐Closas M., Buetow K., Fraumeni J.F. Jr., The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1471: C1–C10, 2001. [DOI] [PubMed] [Google Scholar]
  • 95. Okobia M. N., Bunker C. H., Molecular epidemiology of breast cancer: a review, Afr. J. Reprod. Health, 7: 17–28, 2003. [PubMed] [Google Scholar]
  • 96. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K., Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco‐related cancers, Cancer Epidemiol. Biomarkers Prev., 9: 3–28, 2000. [PubMed] [Google Scholar]
  • 97. Hellmold H., Rylander T., Magnusson M., Reihner E., Warner M., Gustafsson J. A., Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties, J. Clin. Endocrinol. Metab, 83: 886–895, 1998. [DOI] [PubMed] [Google Scholar]
  • 98. Strange R. C., Fryer A. A., The glutathione S‐transferases: influence of polymorphism on cancer susceptibility, IARC Sci. Publ. , 231–249, 1999. [PubMed]
  • 99. Albin N., Massaad L., Toussaint C., Mathieu M. C., Morizet J., Parise O., Gouyette A., Chabot G. G., Main drug‐metabolizing enzyme systems in human breast tumors and peritumoral tissues, Cancer Res., 53: 3541–3546, 1993. [PubMed] [Google Scholar]
  • 100. Gudmundsdottir K., Tryggvadottir L., Eyfjord J. E., GSTM1, GSTT1, and GSTP1 genotypes in relation to breast cancer risk and frequency of mutations in the p53 gene, Cancer Epidemiol. Biomakers Prev., 10: 1169–1173, 2001. [PubMed] [Google Scholar]
  • 101. Freudenheim J. L., Ambrosone C. B., Moysich K. B., Vena J. E., Graham S., Marshall J. R., Muti P., Laughlin R., Nemoto T., Harty L. C., Crits G. A., Chan A. W., Shields P. G., Alcohol dehydrogenase 3 genotype modification of the association of alcohol consumption with breast cancer risk, Cancer Causes Control, 10: 369–377, 1999. [DOI] [PubMed] [Google Scholar]
  • 102. Campbell I. G., Baxter S. W., Eccles D. M., Choong D. Y., Methylenetetrahydrofolate reductase polymorphism and susceptibility to breast cancer, Breast Cancer Res., 4: R14–2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103. Ergul E., Sazci A., Utkan Z., Canturk N. Z., Polymorphisms in the MTHFR gene are associated with breast cancer, Tumour. Biol., 24: 286–290, 2003. [DOI] [PubMed] [Google Scholar]
  • 104. Duell E. J., Millikan R. C., Pittman G. S., Winkel S., Lunn R. M., Tse C. K., Eaton A., Mohrenweiser H. W., Newman B., Bell D. A., Polymorphisms in the DNA Repair Gene XRCC1 and Breast Cancer, Cancer Epidemiol. Biomarkers Prev. 10: 217–222, 2001. [PubMed] [Google Scholar]
  • 105. Smith T. R., Levine E. A., Perrier N. D., Miller M. S., Freimanis R. I., Lohman K., Case L. D., Xu J., Mohrenweiser H. W., Hu J. J., DNA‐repair genetic polymorphisms and breast cancer risk, Cancer Epidemiol. Biomarkers Prev., 12: 1200–1204, 2003. [PubMed] [Google Scholar]
  • 106. Goode E. L., Ulrich C. M., Potter J. D., Polymorphisms in DNA Repair Genes and Associations with Cancer Risk, Cancer Epidemiol. Biomarkers Prev., 11: 1513–1530, 2002. [PubMed] [Google Scholar]
  • 107. Medina D, Breast cancer: the protective effect of pregnancy, Clin. Cancer Res., 10: 380S–384S, 2004. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cellular and Molecular Medicine are provided here courtesy of Blackwell Publishing

RESOURCES